"Hydroxamic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of weak acids with the general formula R-CONHOH.
Descriptor ID |
D006877
|
MeSH Number(s) |
D02.092.570.394 D02.241.511.372
|
Concept/Terms |
Hydroxamic Acids- Hydroxamic Acids
- Acids, Hydroxamic
- Hydroxamic Acid
- Acid, Hydroxamic
|
Below are MeSH descriptors whose meaning is more general than "Hydroxamic Acids".
Below are MeSH descriptors whose meaning is more specific than "Hydroxamic Acids".
This graph shows the total number of publications written about "Hydroxamic Acids" by people in this website by year, and whether "Hydroxamic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2001 | 1 | 2 | 3 |
2002 | 0 | 4 | 4 |
2003 | 3 | 5 | 8 |
2004 | 5 | 3 | 8 |
2005 | 6 | 3 | 9 |
2006 | 4 | 8 | 12 |
2007 | 7 | 6 | 13 |
2008 | 3 | 4 | 7 |
2009 | 8 | 7 | 15 |
2010 | 7 | 9 | 16 |
2011 | 7 | 4 | 11 |
2012 | 9 | 10 | 19 |
2013 | 10 | 12 | 22 |
2014 | 1 | 7 | 8 |
2015 | 12 | 7 | 19 |
2016 | 3 | 6 | 9 |
2017 | 4 | 3 | 7 |
2018 | 0 | 1 | 1 |
2020 | 0 | 4 | 4 |
2022 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxamic Acids" by people in Profiles.
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
-
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro Oncol. 2022 04 01; 24(4):655-664.
-
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2021 05; 62(5):1187-1194.
-
Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells. J Sci Food Agric. 2021 Mar 30; 101(5):1833-1843.
-
Inhibitors of metalloprotease, ?-sectretase, protein kinase C and Rho kinase inhibit wild-type adenoviral replication. PLoS One. 2020; 15(7):e0236175.
-
HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models. Am J Physiol Gastrointest Liver Physiol. 2020 06 01; 318(6):G1022-G1033.
-
ShiF acts as an auxiliary factor of aerobactin secretion in meningitis Escherichia coli strain S88. BMC Microbiol. 2019 12 17; 19(1):298.
-
Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun. 2018 10 01; 6(1):103.
-
Tubastatin A prevents hemorrhage-induced endothelial barrier dysfunction. J Trauma Acute Care Surg. 2018 02; 84(2):386-392.
-
Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. Biotechnol Lett. 2018 Feb; 40(2):249-256.